Drugs / Anastrozol
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy5 trials | ||||||
| Phase 2 | NCT07101159 Background | Sep 2025 → Dec 2031 expected | hormone receptor-positive breast cancer | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT02592083 Background | Oct 2015 → Feb 2019 overdue | hormone receptor-positive breast cancer | Thomas Hatschek | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00935558 Comparator | Jul 2009 → May 2012 | breast cancer | Inge Marie Svane | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT07019363 Comparator | Jun 2025 → May 2029 expected | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT04852887 Comparator | Jun 2021 → Apr 2031 expected | female breast carcinoma | NRG Oncology | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anastrozol | “Letrozol or Anastrozol or Exemestane” NCT02592083 ↗ |
| Known as | Arimidex, anastrozol, AstraZeneca | “Arimidex, anastrozol, AstraZeneca” NCT00935558 ↗ |